Lisa Whittington, PharmD

Panelists discuss how identifying high-risk patients and minimizing unnecessary dopamine-blocking therapy are key steps in reducing the incidence of tardive dyskinesia.

Panelists discuss how early recognition and accurate diagnosis of tardive dyskinesia are vital to improving outcomes and quality of life for affected patients.